Omada Health Q1 Beats Expectations, Raises Guidance; Execution Gains Traction

What happened

Omada Health reported a "milestone quarter" with 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA, while raising its full-year outlook. This marks a significant step toward profitability, as the company had previously guided FY2025 adjusted EBITDA near breakeven. However, the report does not detail Q1 metrics like member growth or GLP-1 prescribing progress, which are critical for sustained momentum. The stock still trades at a discount to its IPO price, reflecting lingering concerns over partner concentration and internal control weaknesses. Investors should watch the upcoming audited FY2025 results and GLP-1 launch for further validation.

Implication

The Q1 earnings beat supports the bull case but does not remove execution overhangs. The company's ability to sustain 40%+ growth and convert GLP-1 into a revenue driver is still unproven. We see $11.50 as attractive entry; trim above $18. Re-assessment after March audited results.

Thesis delta

The Q1 beat raises confidence in near-term execution, shifting the balance from 'wait and see' to 'positive confirmation.' However, the stock's muted reaction suggests the market needs more than one quarter of profitability to re-rate. The thesis remains dependent on the GLP-1 launch and full-year guidance; the odds of a bear case have decreased, but bull case requires further proof.